SLC15A1 Antibody

What is SLC15A1 and what are its primary biological functions?

SLC15A1 functions as an electrogenic proton-coupled amino acid transporter that primarily transports oligopeptides consisting of 2 to 4 amino acids, with a preference for dipeptides. In humans, it is a 708 amino acid protein with a molecular mass of 78.8 kDa located in the cell membrane. It functions with a proton to peptide stoichiometry of 1:1 or 2:1, enabling the absorption of neutral and monovalently charged peptides .

This transporter plays crucial roles in:

• Absorption of dietary di- and tripeptides from the small intestinal lumen

• Mediation of transepithelial transport of muramyl and N-formylated bacterial dipeptides

• Contributing to recognition of pathogenic bacteria by the mucosal immune system

• Transport of synthetic peptides like F5-peptide in the seminiferous epithelium, which has implications for male contraceptive development

As a member of the Proton-dependent oligopeptide transporter (POT/PTR) (TC 2.A.17) protein family, SLC15A1 has well-characterized post-translational modifications, including glycosylation, which may affect its function and localization .

Where is SLC15A1 expressed in mammals and what is its subcellular localization?

SLC15A1 shows tissue-specific expression patterns that vary between species:

In rat testes, immunohistochemistry studies have revealed that SLC15A1 is predominantly located at the tunica propria (peritubular myoid cells), interstitium (Leydig cells), and blood vessel endothelia . A weaker signal is also observed in the nuclei of germ cells. Importantly, SLC15A1 does not localize to the blood-testis barrier (BTB) as it fails to co-localize with BTB tight junction markers like ZO-1 or adhesion junction markers like N-cadherin .

This distribution pattern differs significantly from other drug transporters such as P-gp and MRP1, which are predominantly expressed by Sertoli cells, suggesting distinctive physiological functions in the testes .

What common synonyms should researchers know when searching for SLC15A1 literature?

When conducting literature searches on SLC15A1, researchers should be aware of these alternative designations:

Using multiple search terms when conducting literature reviews will ensure comprehensive coverage of relevant studies .

What types of SLC15A1 antibodies are available and how should researchers select them?

Researchers have several options when selecting SLC15A1 antibodies:

When selecting an antibody, researchers should consider:

• The intended application (Western blot, immunohistochemistry, flow cytometry, etc.)

• Target species reactivity (human, mouse, rat, etc.)

• Clonality (polyclonal vs. monoclonal)

• Validation data available for the specific application

• Previous citations in published literature

For example, Abcam offers a rabbit polyclonal SLC15A1/PEPT1 antibody (ab203043) suitable for Flow Cytometry, IHC-P, and ICC/IF with demonstrated reactivity against human, mouse, rat, chicken, and cow samples .

How can researchers validate the specificity of SLC15A1 antibodies?

Validating antibody specificity is crucial for reliable experimental results. For SLC15A1 antibodies, several approaches are recommended:

• Western blot analysis: A monospecific SLC15A1 antibody should detect a single band at approximately 75 kDa in tissues known to express the protein, such as testis lysates .

• Immunohistochemistry controls:

  • Negative control: Incubate sections with normal IgG from the same species at the same dilution as the primary antibody; this should yield no observable staining

  • Positive tissues: Include known SLC15A1-expressing tissues (small intestine, testis)

  • Cross-reactivity control: Test tissues known not to express SLC15A1 (e.g., Sertoli cells in rat)

• RNAi knockdown validation: Demonstrate reduced signal intensity following specific knockdown of SLC15A1. In rat testes, siRNA-mediated knockdown resulted in approximately 90% decrease in protein levels, with effects persisting for at least 5 days (75% reduction), providing strong evidence of antibody specificity .

• Immunofluorescence co-localization: Verify localization patterns with established markers, such as demonstrating the absence of co-localization between SLC15A1 and BTB markers (ZO-1 or N-cadherin) .

How can researchers successfully knockdown SLC15A1 in experimental models?

RNA interference (RNAi) has been effectively used to knockdown SLC15A1 expression both in vivo and in vitro:

For in vivo knockdown in rat testes:

• Design specific siRNA duplexes targeting the SLC15A1 transcript

• Administer via intratesticular injection

• Include non-targeting siRNA duplexes as negative controls

• Verify knockdown efficiency by Western blot analysis

Experimental data shows that this approach can achieve:

• Approximately 90% reduction in SLC15A1 protein levels within 2 days of transfection

• Sustained knockdown effect for at least 5 days (75% reduction maintained)

The effectiveness of knockdown should be assessed by:

• Protein level (Western blot with specific anti-SLC15A1 antibodies)

• Functional assays (e.g., transport activity measurements)

• Phenotypic effects (e.g., prevention of F5-peptide induced disruption of spermatogenesis)

What immunohistochemistry protocols yield optimal results for SLC15A1 detection?

Based on successful studies in rat testis models, the following protocol guidelines are recommended:

• Tissue preparation:

  • Fix tissue samples appropriately (paraformaldehyde fixation has shown good results)

  • For paraffin embedding, standard processing protocols are suitable

  • Section thickness of 4-5 μm is optimal for cellular detail

• Antigen retrieval:

  • May be necessary depending on fixation method and antibody requirements

• Antibody incubation:

  • Validate optimal dilution for your specific antibody (typically ranges from 1:200 to 1:1000)

  • Include parallel sections for negative controls using normal IgG at identical concentration

• Detection system:

  • Both enzyme-based methods (for brightfield microscopy) and fluorescence-based detection (for co-localization studies) have been successfully employed

• Controls:

  • Positive control: Include tissues with known SLC15A1 expression

  • Negative control: Normal IgG at same dilution as primary antibody

  • Cellular localization control: Co-staining with established markers (e.g., BTB markers like ZO-1)

How does SLC15A1 function relate to male reproductive biology and contraceptive development?

SLC15A1 plays a previously unrecognized role in male reproductive biology:

• Expression pattern in testes:

  • Located at tunica propria (peritubular myoid cells)

  • Present in interstitium (Leydig cells)

  • Found in blood vessel endothelia

  • Detected in germ cell nuclei

  • Notably absent from the blood-testis barrier (BTB)

• Role in peptide transport:

  • Functions as a carrier for synthetic F5-peptide (a 50-amino acid polypeptide)

  • Facilitates F5-peptide entry into the seminiferous epithelium

• Contraceptive implications:

  • F5-peptide (320 μg/testis) administered via intratesticular injection causes disruption of spermatogenesis

  • Effects include germ cell depletion from the epithelium, particularly affecting elongated, elongating or round spermatids and late spermatocytes

  • Knockdown of SLC15A1 prevents these F5-peptide induced effects

  • Tubule diameter reduction of approximately 20% observed in affected tubules

This research establishes SLC15A1 as a novel target that could be genetically modified to improve the bioavailability of peptide-based male contraceptives .

How does SLC15A1 contribute to drug absorption and bioavailability studies?

SLC15A1 plays a significant role in drug absorption and bioavailability:

• Transport mechanism:

  • Proton-coupled transport with stoichiometry of 1:1 or 2:1 (proton:peptide)

  • Transports neutral and monovalently charged peptides

  • Primarily functions in the small intestine for absorption of di- and tripeptides

• Pharmaceutical applications:

  • Serves as a promising target for facilitating intestinal absorption of prodrugs

  • Can be leveraged for drug delivery strategies, particularly for peptide-based therapeutics

  • Understanding SLC15A1 transport kinetics helps predict oral bioavailability of peptide-like drugs

• Experimental approaches:

  • Cell-based transport assays using SLC15A1-expressing cell lines

  • In vivo pharmacokinetic studies comparing wild-type and SLC15A1 knockdown models

  • Structure-activity relationship studies to optimize drug moieties for SLC15A1-mediated transport

Researchers studying drug absorption should consider SLC15A1's substrate specificity, tissue expression patterns, and potential for genetic variation when designing experiments to evaluate oral bioavailability .

How does SLC15A1 participate in immune response to bacterial peptides?

SLC15A1 contributes to immune surveillance by:

• Transporting bacterial peptide signatures:

  • Mediates transepithelial transport of muramyl peptides

  • Facilitates absorption of N-formylated bacterial dipeptides

• Immune recognition function:

  • This transport activity contributes to the recognition of pathogenic bacteria

  • Enables the mucosal immune system to detect bacterial components

  • Provides an interface between luminal bacterial content and immune surveillance mechanisms

This dual role in both nutritional peptide absorption and immune-related peptide transport highlights SLC15A1's multifunctional nature. Researchers investigating host-pathogen interactions should consider SLC15A1 as a potential mediator in immune recognition pathways, particularly in intestinal and other epithelial barrier tissues .

What experimental conditions can affect SLC15A1 expression and function?

Several factors can influence SLC15A1 expression and function in experimental systems:

• Tissue-specific regulation:

  • High expression in small intestine

  • Differential expression across testicular cell types (present in germ cells, myoid cells, Leydig cells; absent in Sertoli cells)

• Species differences:

  • Orthologs identified in mouse, rat, bovine, frog, chimpanzee and chicken

  • Expression patterns may vary between species

  • Consider species-appropriate antibodies for cross-species studies

• Post-translational modifications:

  • Glycosylation affects protein folding, trafficking, and function

  • May vary between tissue types and experimental conditions

• Experimental manipulations:

  • RNAi can achieve 75-90% knockdown for 5+ days in rat testis

  • Effects of knockdown on specific phenotypes (e.g., F5-peptide response) can be quantified

• Subcellular localization variations:

  • Cell membrane localization in intestinal epithelium

  • Nuclear localization in germ cells

  • No localization at blood-testis barrier

Researchers should control for these variables and include appropriate controls when designing experiments involving SLC15A1 .

How can researchers distinguish between specific and non-specific binding when using SLC15A1 antibodies?

Distinguishing specific from non-specific binding requires systematic controls:

• Antibody validation:

  • Verify monospecificity by Western blot (should show single band at ~75 kDa)

  • Confirm reduction/elimination of signal with SLC15A1 knockdown (90% protein reduction should correspond to proportional signal reduction)

• Control tissues:

  • Negative cellular control: In rat testis, Sertoli cells lack SLC15A1 expression

  • Positive control: Small intestine or testicular tissues with known expression

• Immunohistochemistry/immunofluorescence controls:

  • Use normal IgG at identical concentration as primary antibody

  • Should yield no observable staining, in contrast to specific SLC15A1 antibody signal

  • Co-staining with markers of known structures (e.g., BTB markers like ZO-1 or N-cadherin should not co-localize with SLC15A1)

• Signal specificity verification:

  • Compare signal patterns with known localization (e.g., tunica propria, interstitium, blood vessel endothelia, and germ cell nuclei in rat testes)

  • Verify absence of signal where SLC15A1 is not expressed (e.g., blood-testis barrier)

What are the common pitfalls in SLC15A1 functional studies?

When conducting functional studies of SLC15A1, researchers should be aware of these potential pitfalls: